|
BIIB's Revenue Growth by Quarter and Year
Biogen Inc 's Revenue results by quarter and year
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| BIIB Revenue (in millions $) |
FY 2020 |
FY 2019 |
FY 2018 |
FY 2017 |
| IV Quarter |
December |
2,852.60
|
3,671.30
|
3,526.30
|
3,307.00
|
| III Quarter |
September |
3,376.10
|
3,600.10
|
3,439.00
|
3,077.80
|
| II Quarter |
June |
3,681.60
|
3,616.70
|
3,356.50
|
3,078.40
|
| I Quarter |
March |
3,534.30
|
3,489.80
|
3,131.10
|
2,810.70
|
| FY |
|
13,444.60
|
14,377.90
|
13,452.90
|
12,273.90
|
| BIIB Revenue forth quarter 2020 Y/Y Growth Comment |
Biogen Inc reported decline in Revenue in the forth quarter by -22.3% to $ 2,852.60 millions, from the same quarter in 2019.
This represents worst decline in recent Company history.
Looking into forth quarter results within Biotechnology & Drugs industry 66 other companies have achieved higher Revenue growth. While Biogen Inc ' s Revenue fall of -22.3% ranks overall at the positon no. 2645 in the forth quarter.
|
| BIIB Revenue ( Y/Y Growth %) |
2020
|
2019 |
2018 |
2017 |
| IV Quarter |
December |
-22.3 % |
4.11 % |
6.63 % |
15.15 % |
| III Quarter |
September |
-6.22 % |
4.68 % |
11.74 % |
4.13 % |
| II Quarter |
June |
1.79 % |
7.75 % |
9.03 % |
6.36 % |
| I Quarter |
March |
1.28 % |
11.46 % |
11.4 % |
3.08 % |
| FY |
|
-6.49 % |
6.88 % |
9.61 % |
7.21 % |
BIIB Revenue (Quarter on Quarter Growth %) |
2020
|
2019 |
2018 |
2017 |
| IV Quarter |
December |
-15.51 % |
1.98 % |
2.54 % |
7.45 % |
| III Quarter |
September |
-8.3 % |
-0.46 % |
2.46 % |
-0.02 % |
| II Quarter |
June |
4.17 % |
3.64 % |
7.2 % |
9.52 % |
| I Quarter |
March |
-3.73 % |
-1.04 % |
-5.32 % |
-2.13 % |
| FY (Year on Year) |
|
-6.49 % |
6.88 % |
9.61 % |
7.21 % |
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 96.03 % |
13.82 % |
-22.3 % |
| (Dec. 31, 2004) |
|
(Dec 31 2020) |
|
|
| Revenue Y/Y Growth Statistics |
| High |
Average |
Low |
| 96.03 % |
13.82 % |
-22.3 % |
| (Dec. 31, 2004) |
|
(Dec 31 2020) |
|
| Revenue by Quarter for the Fiscal Years 2017, 2018, 2019, 2020 |
Biogen Inc 's Q/Q Revenue Growth
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 80.67 % |
3.81 % |
-15.51 % |
| (March 31, 2004) |
|
|
| BIIB's IV. Quarter Q/Q Revenue Comment |
In the IV. Quarter 2020 Biogen Inc realized fall in Revenue sequentially by -15.51% to $ 2,852.60 millions, from $ 3,376.10 millions declared in the previous reporting period.
Even periodic influence were not able to rescue the IV. Quarter for the Biogen Inc , Aarush Khan , Healthcare sector researcher wrote.
Within Biotechnology & Drugs industry 75 other companies have achieved higher Revenue quarter on quarter growth. While Biogen Inc 's Revenue growth quarter on quarter, overall rank is 2772. |
|
|
|
| Revenue Q/Q Growth Statistics |
| High |
Average |
Low |
| 80.67 % |
3.81 % |
-15.51 % |
| (March 31, 2004) |
|
|
| BIIB's IV. Quarter Q/Q Revenue Comment |
In the IV. Quarter 2020 Biogen Inc disclosed fall in Revenue sequentially by -15.51% to $ 2,852.60 millions, from $ 3,376.10 millions achived in the previous quarter.
Although cyclical influence commonly fuel IV. Quarter 2020 Revenue, this clearly was not substantial to salvage Biotechnology & Drugs's company IV. Quarter 2020 performance, Aarush Khan , Healthcare sector researcher pointed out.
Within Biotechnology & Drugs industry 75 other companies have achieved higher Revenue quarter on quarter growth. While Biogen Inc 's Revenue growth quarter on quarter, overall rank is 2772. |
|
Biogen Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth |
12 Months Ending
(Dec 31 2020) |
12 Months Ending
(Sep 30 2020) |
12 Months Ending
(Jun 30 2020) |
12 Months Ending
(Mar 31 2020) |
12 Months Ending
(Dec 31 2019) |
| Cumulative Revenue 12 Months Ending |
$ 13,444.60 |
$ 14,263.30 |
$ 14,487.30 |
$ 14,422.40 |
$ 14,377.90 |
| Y / Y Revenue Growth (TTM) |
-6.49 % |
0.21 % |
2.95 % |
4.42 % |
6.88 % |
| Year on Year Revenue Growth Overall
Ranking |
# 1609 |
# 1655 |
# 53 |
# 1547 |
# 1266 |
| Seqeuential Revenue Change (TTM) |
-5.74 % |
-1.55 % |
0.45 % |
0.31 % |
1.02 % |
| Seq. Revenue Growth (TTM) Overall
Ranking |
# 2868 |
# 2396 |
# 35 |
# 1639 |
# 1590 |
| Cumulative Revenue growth
Comment |
For the 12 months ended Dec 31 2020 Biogen Inc reported a decrease in Revenue by -6.49% year on year, to $13,445 millions, compare to the 0.21% growth at Sep 30 2020.
In the Healthcare sector 245 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1609, from total ranking in previous quarter at 1655. |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
10.31 % |
2.95 % |
-5.74 % |
|
|
|
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
41.42 % |
13.27 % |
-6.49 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 83 |
| Sector |
# 402 |
| S&P 500 |
# 2868 |
|
| Cumulative Revenue growth
Comment |
For the 12 months ended Dec 31 2020 Biogen Inc reported a decrease in Revenue by -6.49% year on year, to $13,445 millions, compare to the 0.21% growth at Sep 30 2020.
In the Healthcare sector 245 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1609, from total ranking in previous quarter at 1655. |
| Revenue TTM Q/Q Growth Statistics |
| High |
Average |
Low |
10.31 % |
2.95 % |
-5.74 % |
|
|
|
| Revenue TTM Y/Y Growth Statistics |
| High |
Average |
Low |
41.42 % |
13.27 % |
-6.49 % |
|
|
|
| Revenue TTM Q/Q Growth Company Ranking |
| Within: |
No. |
| Industry |
# 83 |
| Sector |
# 402 |
| S&P 500 |
# 2868 |
|
